Rose-Waaler Brucella Agglutination Test

Dr. Neha Sharma

Introduction

  • It is a serological test used to detect Brucella-specific antibodies in human serum.
  • Brucella are intracellular bacteria that cause brucellosis, a zoonotic disease.
  • Brucellosis commonly causes fever, weakness, sweating, and systemic symptoms.
  • Infection may occur through contact with infected animals, consumption of unpasteurized dairy products, or inhalation of contaminated aerosols.
  • The immune system produces antibodies against Brucella antigens after infection.
  • The test uses inactivated Brucella antigens to detect antibodies in the patient’s serum.
  • These antibodies react with the antigen and produce visible agglutination (clumping).
  • The test can detect mainly IgM and IgG antibodies, depending on the antigen and testing method.
  • It is useful as a screening/supportive test for brucellosis.
  • Results should be interpreted along with clinical findings and exposure history.

Principle

  • Agglutination is an antigen–antibody reaction.
  • It occurs when specific antibodies react with particulate antigens.
  • In the Rose-Waaler test, Brucella antigen is mixed with the patient’s serum.
  • If Brucella-specific antibodies are present, they bind to the antigen.
  • The antibodies cross-link the antigen particles.
  • This produces visible clumping or agglutination.
  • Visible clumping = Positive reaction.
  • No clumping = Negative reaction.

Requirements

Sample

  • Type: Serum (preferred). Plasma (EDTA or heparinized) may also be used.
  • Volume: 2–3 mL of venous blood is sufficient.
  • Collection and Storage:
    • Use sterile equipment to collect blood and centrifuge promptly to obtain serum.
    • Store serum at 2–8°C if testing within 72 hours; for extended storage, freeze at −20°C. Avoid multiple freeze-thaw cycles.

Reagents and Materials

  1. Brucella Antigen:
    • Prepared from killed Brucella abortus, B. melitensis, or B. suis. The antigens may be stained with dyes like Rose Bengal for better visibility.
  2. Diluent:
    • Normal saline or phosphate-buffered saline (PBS) for preparing serial dilutions.
  3. Positive Control Serum:
    • A serum sample with a known Brucella antibody titer was used to validate the test.
  4. Negative Control Serum:
    • CRP-free serum or saline to ensure test specificity.
  5. Glassware and Equipment:
    • Clean glass slides (for qualitative testing).
    • Tubes for serial dilutions in quantitative testing.
    • Pipettes (automatic or manual) for accurate reagent handling.
    • Tube racks and a calibrated rotator (if required).
  6. Other Items:
    • Micropipettes, mixing sticks, and disposable tips.
    • Timer to monitor reaction time.

Procedure

Slide Agglutination Test (Qualitative Method)

This is a rapid screening method to detect the presence of Brucella antibodies.

Steps:

  1. Bring the patient serum and Brucella antigen to room temperature.
  2. Take a clean, dry glass slide.
  3. Place the required amount of patient serum on the slide.
  4. Add the recommended amount of Brucella antigen to the serum.
  5. Mix the serum and antigen thoroughly using a clean applicator.
  6. Gently rock or rotate the slide for the recommended time.
  7. Observe the mixture for visible agglutination (clumping).
  8. Compare the reaction with the positive and negative controls.

Interpretation:

  • Positive: Visible clumping indicates the presence of antibodies against Brucella.
  • Negative: No clumping indicates the absence of detectable antibodies.

Tube Agglutination Test (Quantitative Method)

This method determines the antibody titer in the patient’s serum through serial dilutions.

Steps:

  1. Collect the patient’s serum and prepare the required serial dilutions.
  2. Label a series of test tubes with the appropriate serum dilutions.
  3. Prepare serial dilutions, for example: 1:20, 1:40, 1:80, 1:160, 1:320.
  4. Add a standardized amount of Brucella antigen to each tube.
  5. Mix the contents of each tube properly.
  6. Include appropriate positive and negative controls.
  7. Incubate the tubes according to the manufacturer’s instructions.
  8. Examine the tubes for visible agglutination.
  9. Determine the highest serum dilution showing a definite positive agglutination reaction.
  10. This highest positive dilution is reported as the antibody titer.
  11. A higher titer indicates a greater level of detectable Brucella antibodies, but the result must be interpreted with clinical findings and local laboratory criteria.

Interpretation:

  • The highest serum dilution showing at least 50% agglutination is recorded as the antibody titer.

Results

Qualitative Results:

  • Positive: Presence of agglutination (clumping). Indicates exposure to Brucella.
  • Negative: Absence of agglutination. No detectable antibodies.

Quantitative Results:

  • Titer: Expressed as the reciprocal of the highest serum dilution, showing significant agglutination.

Diagnostic Criteria:

  • <1:40: Negative or insignificant titer, unlikely brucellosis.
  • 1:80 to 1:160: Suggestive of exposure or early infection.
  • >1:160: Indicates active infection or significant exposure.

Clinical Significance

  1. Diagnosis of Brucellosis:
    • A positive result strongly supports the diagnosis, especially when correlated with clinical signs like fever, sweating, joint pain, and hepatosplenomegaly.
  2. Monitoring Disease Progression:
    • Rising titers in sequential tests confirm an ongoing or worsening infection.
    • Decreasing titers indicates recovery or successful treatment.
  3. Differential Diagnosis:
    • Helps differentiate brucellosis from other febrile illnesses.
  4. Epidemiological Surveillance:
    • Useful in regions where brucellosis is endemic, especially among occupationally exposed groups (e.g., farmers, and veterinarians).

Limitations

  1. Non-Specificity:
    • Cross-reactivity with other Gram-negative bacteria, such as Yersinia enterocolitica, Escherichia coli, or Francisella tularensis, may produce false positives.
  2. Timing of Testing:
    • Antibodies may not be detectable during the early stages of infection. A repeat test after 1–2 weeks is recommended for better sensitivity.
  3. Chronic Brucellosis:
    • Persistently high antibody titers may indicate chronic infection but do not always indicate active disease.
  4. Test Performance:
    • The sensitivity and specificity depend on the quality of antigens and reagents used.

Precautions

  1. Sample Collection:
    • Avoid hemolysis or contamination during blood collection.
  2. Reagent Quality:
    • Ensure standardized Brucella antigens and proper storage conditions.
  3. Correlate with Clinical Data:
    • Positive results must always be interpreted alongside clinical findings and other diagnostic tests, such as PCR or blood culture.
  4. Repeat Testing:
    • Repeating testing with serial samples may provide clarity if initial results are inconclusive.